Back

Chronic TGFβ1 Signaling Drives Aberrant Alveolar-Basaloid Metaplasia through a KRT17-Stratifin migratory complex

Sahasrabudhe, I. R.; Ma, X.; Iantorno, S. A.; Tran, T.; Dsouza, S.; Sussman, C.; Jones, D.; Biscotti, M.; Cao, I.; Katzen, J.; Basil, M. C.; Hook, J. L.; Alysandratos, K.-D.; Kathiriya, J. J.

2026-05-17 cell biology
10.64898/2026.05.17.724675 bioRxiv
Show abstract

Chronic fibrotic disorders like idiopathic pulmonary fibrosis (IPF) are characterized by aberrant alveolar regeneration and severely limited treatment options. Identification of the mechanisms driving aberrant epithelial repair can lead to new viable therapeutic targets. Using integrated single nucleus ATAC- and RNA-sequencing on human lungs and an in vitro model of dysplastic repair, we identify two distinct regenerative trajectories for alveolar type 2 (AT2) cells: a resolvable euplastic repair trajectory and a persistent, non-resolving dysplastic repair trajectory. The latter is governed by a spatially restricted ITGB6/TGF{beta}1/SMAD3 signaling axis in fibrotic regions of IPF lungs and in murine lungs characterized by chronic epithelial remodeling. Mechanistically, SMAD3 directly regulates dysplastic transitional cell (DTC) markers, including KRT17 and Stratifin. We show that TGF{beta}1 signaling promotes a physical interaction between KRT17 and Stratifin at the leading edge of migrating DTCs in vitro and in vivo, which is essential for their migratory capacity. These findings collectively define the molecular regulation of AT2-driven dysplastic regeneration and identify TGF{beta}1-induced KRT17-Stratifin axis as a central driver of pathological epithelial remodeling in chronic fibrosis, which can be targeted therapeutically to tilt the balance in favor of euplastic regeneration.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Developmental Cell
168 papers in training set
Top 0.6%
18.3%
2
Nature Cell Biology
99 papers in training set
Top 0.1%
14.1%
3
Nature
575 papers in training set
Top 3%
9.9%
4
Nature Communications
4913 papers in training set
Top 19%
9.9%
50% of probability mass above
5
Cell Stem Cell
57 papers in training set
Top 0.2%
6.2%
6
Cell Reports
1338 papers in training set
Top 17%
3.0%
7
Molecular Cell
308 papers in training set
Top 6%
2.3%
8
Science Advances
1098 papers in training set
Top 13%
2.0%
9
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 30%
1.9%
10
Immunity
58 papers in training set
Top 2%
1.9%
11
Journal of Experimental Medicine
106 papers in training set
Top 2%
1.7%
12
Advanced Science
249 papers in training set
Top 12%
1.7%
13
eLife
5422 papers in training set
Top 43%
1.7%
14
Cell
370 papers in training set
Top 12%
1.7%
15
Journal of Clinical Investigation
164 papers in training set
Top 3%
1.6%
16
Nature Immunology
71 papers in training set
Top 1%
1.6%
17
Nature Genetics
240 papers in training set
Top 5%
1.3%
18
JCI Insight
241 papers in training set
Top 5%
1.2%
19
Science
429 papers in training set
Top 17%
1.2%
20
Cancer Discovery
61 papers in training set
Top 2%
0.9%
21
Nature Aging
51 papers in training set
Top 2%
0.9%
22
Cell Systems
167 papers in training set
Top 11%
0.9%
23
The EMBO Journal
267 papers in training set
Top 5%
0.8%
24
Nature Medicine
117 papers in training set
Top 5%
0.8%
25
Science Translational Medicine
111 papers in training set
Top 6%
0.7%
26
Nature Structural & Molecular Biology
218 papers in training set
Top 5%
0.7%
27
EMBO reports
136 papers in training set
Top 8%
0.6%